With the label extension, Eylea 8mg would be the only anti-VEGF approved for a treatment interval of six months. Roche’s Vabysmo became the first bispecific antibody approved for the eye.

Regeneron Pharmaceuticals (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics license application ((sBLA)) for Eylea HD injection, 8 mg, to treat macular ...

TARRYTOWN, N.Y., Aug. 17, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administ ...

Global sales for Regeneron Pharmaceuticals' key drug Eylea in 1Q16 stood at $1.2 billion. ... US Treasury Bonds Rates. Currency Converter. News. Latest News. From the Newsroom.

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

Results from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer's Eylea is the most effective. The trial was sponsored by the US government-funded ...

Roche’s wet AMD drug Lucentis already has DME on its label. As FiercePharma pointed out, Eylea’s two existing indications—wet AMD and for macular edema following central retinal vein occlusion ...

US regulators have given the all clear for using Regeneron’s Eylea (aflibercept) to treat Diabetic Macular Odema, a common complication of diabetes and a leading cause of vision loss among working age ...

While low-dose Eylea loses US patent protection in 2027, a high-dose version, Eylea HD, launched in late 2023 with patent protection through 2039, allowing continued strong cash flows in ...

Lucentis still selling more than Eylea by value but is showing signs of weakness with Roche reporting US sales down 9% in the first quarter of the year to €394m and Novartis ... – used off-label – in ...

Bayer’s retinal disease treatment Eylea (aflibercept) is set for an extended treatment interval, a label extension that could give the drug an advantage over rival Roche’s Vabysmo (faricimab ...

Eylea’s US sales are recorded by Regeneron Pharmaceuticals (REGN), whereas non-US sales are reported by Bayer HealthCare. Excluding Japan, the two equally share the profits or losses for the drug.